Top-Rated StocksTop-RatedNASDAQ:INSM Insmed (INSM) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free INSM Stock Alerts $27.13 -0.19 (-0.70%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$27.01▼$27.5550-Day Range$25.72▼$29.5152-Week Range$16.25▼$32.00Volume1.13 million shsAverage Volume1.65 million shsMarket Capitalization$4.03 billionP/E RatioN/ADividend YieldN/APrice Target$45.10 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Insmed alerts: Email Address Insmed MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside66.2% Upside$45.10 Price TargetShort InterestBearish5.95% of Shares Sold ShortDividend StrengthN/ASustainability-1.32Upright™ Environmental ScoreNews Sentiment0.92Based on 3 Articles This WeekInsider TradingSelling Shares$2.91 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.65) to ($3.81) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.90 out of 5 starsMedical Sector246th out of 938 stocksPharmaceutical Preparations Industry105th out of 417 stocks 3.5 Analyst's Opinion Consensus RatingInsmed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $45.10, Insmed has a forecasted upside of 66.2% from its current price of $27.13.Amount of Analyst CoverageInsmed has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.95% of the outstanding shares of Insmed have been sold short.Short Interest Ratio / Days to CoverInsmed has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Insmed has recently increased by 3.15%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldInsmed does not currently pay a dividend.Dividend GrowthInsmed does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInsmed has received a 67.11% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Aminoglycosides", "Preclinical research services for physical health", and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Insmed is -1.32. Previous Next 3.3 News and Social Media Coverage News SentimentInsmed has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Insmed this week, compared to 3 articles on an average week.Search Interest11 people have searched for INSM on MarketBeat in the last 30 days. This is an increase of 57% compared to the previous 30 days.MarketBeat Follows10 people have added Insmed to their MarketBeat watchlist in the last 30 days. This is an increase of 233% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Insmed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,909,520.00 in company stock.Percentage Held by InsidersOnly 4.30% of the stock of Insmed is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Insmed are expected to grow in the coming year, from ($4.65) to ($3.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Insmed is -5.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Insmed is -5.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressA lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. Click here to jump in on the next one About Insmed Stock (NASDAQ:INSM)Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.Read More INSM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INSM Stock News HeadlinesMarch 27, 2024 | finance.yahoo.comInsmed to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International ConferenceMarch 19, 2024 | markets.businessinsider.comStrong Endorsement and Market Expansion Potential Justify Buy Rating for Insmed’s BrensocatibMarch 29, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…March 17, 2024 | finance.yahoo.comINSM Apr 2024 25.000 putMarch 15, 2024 | markets.businessinsider.comCrinetics Pharmaceuticals Earns ‘Buy’ Rating on Clinical Success and Market Expansion PotentialMarch 13, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Insmed (INSM), Oric Pharmaceuticals (ORIC) and CytomX Therapeutics (CTMX)March 12, 2024 | yahoo.comJane Seymour Talks 'Unseenism,' Aging, Advocating for Yourself and MoreMarch 11, 2024 | msn.comJane Seymour Slams Ageism Against Women: ‘It’s a Real, Really Large Issue’March 29, 2024 | Insiders Exposed (Ad)This consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.March 7, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Insmed (INSM) and Zimmer Biomet Holdings (ZBH)March 1, 2024 | msn.comJane Seymour raises awareness about 'unseenism' after she feels ignored and overlooked as she gets olderMarch 1, 2024 | msn.comJane Seymour Talks About Being ‘Unseen’ as She Ages, Says Men ‘Look Over My Head and Find the Nearest Man’ To Talk ToFebruary 29, 2024 | prnewswire.comInsmed To Present at Three March ConferencesFebruary 28, 2024 | finance.yahoo.comActress Jane Seymour and Insmed Raise Awareness of "Unseenism" and Empower People to Speak Up When It Comes to Their HealthFebruary 28, 2024 | markets.businessinsider.comBuy Rating Affirmed for Insmed on Positive Pipeline Prospects and Robust Revenue ForecastsFebruary 27, 2024 | msn.comUBS Initiates Coverage of Insmed (INSM) with Buy RecommendationFebruary 26, 2024 | markets.businessinsider.comBuy Rating Affirmed for Insmed on Strong Sales and Promising Trial OutlookFebruary 24, 2024 | finance.yahoo.comInsmed Full Year 2023 Earnings: EPS Misses ExpectationsFebruary 23, 2024 | markets.businessinsider.comBuy Recommendation for Insmed: Underestimated Drug Potential and Solid FinancialsFebruary 23, 2024 | finance.yahoo.comInsmed Incorporated (NASDAQ:INSM) Q4 2023 Earnings Call TranscriptFebruary 23, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Insmed (INSM) and BioMarin Pharmaceutical (BMRN)February 22, 2024 | sfgate.comInsmed: Q4 Earnings SnapshotFebruary 22, 2024 | markets.businessinsider.comInsmed Posts Wider Loss In Q4 - Quick FactsFebruary 22, 2024 | finance.yahoo.comInsmed Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Business UpdateFebruary 22, 2024 | prnewswire.comInsmed Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Business UpdateFebruary 21, 2024 | markets.businessinsider.comWhat Wall Street expects from Insmed's earningsFebruary 15, 2024 | finance.yahoo.comInsmed (INSM) Expected to Beat Earnings Estimates: Should You Buy?See More Headlines Receive INSM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Insmed and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today3/28/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:INSM CUSIPN/A CIK1104506 Webwww.insmed.com Phone908-977-9900Fax732-438-0381Employees373Year FoundedN/APrice Target and Rating Average Stock Price Target$45.10 High Stock Price Target$55.00 Low Stock Price Target$36.00 Potential Upside/Downside+66.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($5.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-749,570,000.00 Net Margins-245.59% Pretax Margin-244.76% Return on EquityN/A Return on Assets-53.34% Debt Debt-to-Equity RatioN/A Current Ratio4.12 Quick Ratio3.75 Sales & Book Value Annual Sales$305.21 million Price / Sales13.20 Cash FlowN/A Price / Cash FlowN/A Book Value($2.32) per share Price / Book-11.69Miscellaneous Outstanding Shares148,490,000Free Float142,107,000Market Cap$4.03 billion OptionableOptionable Beta0.92 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. William H. Lewis J.D. (Age 50)Pres, CEO & Chairman Mr. Paolo Tombesi (Age 55)Chief Financial Officer Ms. Christine A. Pellizzari J.D. (Age 51)Chief Legal Officer & Corp. Sec. Mr. Roger Adsett (Age 50)Chief Commercial Officer Dr. Paul D. Streck (Age 55)Advisor Key CompetitorsPerrigoNYSE:PRGOUltragenyx PharmaceuticalNASDAQ:RARECymaBay TherapeuticsNASDAQ:CBAYChemoCentryxNASDAQ:CCXIAxsome TherapeuticsNASDAQ:AXSMView All CompetitorsInsiders & InstitutionsNomura Holdings Inc.Bought 11,010 shares on 3/27/2024Ownership: 0.007%Kingdon Capital Management L.L.C.Bought 405,000 shares on 3/18/2024Ownership: 0.273%Vanguard Group Inc.Sold 219,991 shares on 3/11/2024Ownership: 9.513%Goldman Sachs Group Inc.Sold 101,746 shares on 3/1/2024Ownership: 0.513%American International Group Inc.Bought 2,921 shares on 2/28/2024Ownership: 0.046%View All Insider TransactionsView All Institutional Transactions INSM Stock Analysis - Frequently Asked Questions Should I buy or sell Insmed stock right now? 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last twelve months. There are currently 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" INSM shares. View INSM analyst ratings or view top-rated stocks. What is Insmed's stock price target for 2024? 10 equities research analysts have issued twelve-month price targets for Insmed's shares. Their INSM share price targets range from $36.00 to $55.00. On average, they expect the company's stock price to reach $45.10 in the next year. This suggests a possible upside of 66.2% from the stock's current price. View analysts price targets for INSM or view top-rated stocks among Wall Street analysts. How have INSM shares performed in 2024? Insmed's stock was trading at $30.99 at the beginning of the year. Since then, INSM shares have decreased by 12.5% and is now trading at $27.13. View the best growth stocks for 2024 here. When is Insmed's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our INSM earnings forecast. How were Insmed's earnings last quarter? Insmed Incorporated (NASDAQ:INSM) posted its quarterly earnings results on Thursday, February, 22nd. The biopharmaceutical company reported ($1.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.13) by $0.15. The biopharmaceutical company had revenue of $83.70 million for the quarter, compared to analyst estimates of $82.15 million. The firm's revenue was up 41.1% on a year-over-year basis. During the same quarter last year, the firm earned ($1.20) earnings per share. What ETFs hold Insmed's stock? ETFs with the largest weight of Insmed (NASDAQ:INSM) stock in their portfolio include BNY Mellon Innovators ETF (BKIV), Virtus LifeSci Biotech Products ETF (BBP), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).Principal Healthcare Innovators ETF (BTEC). What guidance has Insmed issued on next quarter's earnings? Insmed updated its FY 2024 earnings guidance on Saturday, February, 24th. The company provided EPS guidance of for the period. The company issued revenue guidance of $340.0 million-$360.0 million, compared to the consensus revenue estimate of $359.5 million. What is Will Lewis' approval rating as Insmed's CEO? 14 employees have rated Insmed Chief Executive Officer Will Lewis on Glassdoor.com. Will Lewis has an approval rating of 78% among the company's employees. What other stocks do shareholders of Insmed own? Based on aggregate information from My MarketBeat watchlists, some companies that other Insmed investors own include Gilead Sciences (gild), AbbVie (ABBV), Johnson & Johnson (JNJ), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA) and Geron (GERN). Who are Insmed's major shareholders? Insmed's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.87%), Vanguard Group Inc. (9.51%), Price T Rowe Associates Inc. MD (7.52%), Palo Alto Investors LP (3.85%), Bellevue Group AG (1.60%) and Norges Bank (1.02%). Insiders that own company stock include David R Brennan, John Drayton Wise, Martina MD Flammer, Melvin Md Sharoky, Michael Alexander Smith, Orlov S Nicole Schaeffer, Roger Adsett, Sara Bonstein and William Lewis. View institutional ownership trends. How do I buy shares of Insmed? Shares of INSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:INSM) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the MarketsBill Gates is all about this tiny $2 stockTimothy SykesMost important medical advance in 100 yearsThe Oxford ClubThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insmed Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.